Stock Markets July 15, 2026 06:20 AM

Erica Schwartz Faces Senate Health Panel in Bid to Lead CDC amid Measles and Ebola Crises

Nominee’s confirmation hearing will test prospects for steady leadership at the agency after a year of upheaval

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn

Erica Schwartz, nominated by President Trump to serve as director of the U.S. Centers for Disease Control and Prevention, is scheduled to appear before the Senate Committee on Health, Education, Labor and Pensions for a confirmation hearing. The session will probe whether the agency can establish durable leadership following multiple high-profile departures and policy clashes, while managing rising measles cases, an international Ebola outbreak and declining public trust in vaccines.

Erica Schwartz Faces Senate Health Panel in Bid to Lead CDC amid Measles and Ebola Crises
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Erica Schwartz, nominated in April, will appear before the Senate Health, Education, Labor and Pensions Committee for a confirmation hearing.
  • The CDC has lacked a confirmed director for nearly all of President Trump’s second term, following rapid turnover including the brief tenure and firing of Susan Monarez.
  • If confirmed, Schwartz will lead the agency during a severe U.S. measles resurgence and an international Ebola outbreak; the committee will also review Sean Kaufman’s nomination for a preparedness role.

Erica Schwartz, President Trump’s choice to lead the U.S. Centers for Disease Control and Prevention, will testify before the Senate Committee on Health, Education, Labor and Pensions on Wednesday in a confirmation hearing that will probe the agency’s ability to regain stable leadership after a period of turbulence.

Trump nominated Schwartz, his first-term deputy surgeon general, in April. The CDC has been without a confirmed director for almost the entirety of President Trump’s second term - holding a confirmed leader for only a single month. The upcoming hearing is the first formal step toward installing a permanent CDC director since Susan Monarez was confirmed last year and then removed from the post less than a month later after policy disagreements with Health Secretary Robert F. Kennedy Jr. over vaccines.

Earlier this year, in March 2025, President Trump withdrew his initial CDC nominee, former Congressman Dave Weldon, hours before a planned hearing. Weldon, a Florida Republican and physician who has been long critical of vaccines, was pulled after it became clear he did not have the necessary votes to secure confirmation.

Schwartz, a board-certified preventive medicine physician, does not have a public record of opposing vaccines and is viewed as a more conventional choice for the role. If the Senate confirms her, she will take the helm of the agency at a challenging moment for public health in the United States and abroad.

The CDC is confronting a resurgence of measles in the United States described as the worst in more than three decades. U.S. measles cases this year are on track to surpass the total recorded in 2025, which was the highest since the disease was declared eliminated in 2000. Public health officials attribute the increase largely to falling childhood immunization rates.

At the same time, the CDC has activated its highest level of emergency response to an Ebola outbreak affecting the Democratic Republic of Congo and Uganda, a response to an outbreak that is now one of the largest on record. The combination of domestic vaccine hesitancy and a major international outbreak has contributed to eroding public confidence in vaccination programs.

Senator Bill Cassidy, a physician and Republican from Louisiana who has expressed skepticism about Health Secretary Kennedy’s approach to vaccine policy, will preside over the hearing. Cassidy described Schwartz as "very impressive" following a meeting with her last month.

The committee will also consider Sean Kaufman, President Trump’s nominee to be assistant secretary for preparedness and response. Kaufman’s nomination has attracted scrutiny because of past statements questioning vaccines, presenting a sharp contrast with Schwartz. Kaufman has publicly questioned the hepatitis B vaccine for infants and has previously invoked the now-disproven claim linking vaccines to autism.

In a May 2025 LinkedIn post that has since been deleted, Kaufman argued against the infant hepatitis B shot and wrote that anyone calling him "an antivaxxer" would force him "to call you a pedophile." As co-founder of a biosafety consulting firm, Kaufman would, if confirmed, oversee national crisis countermeasures including vaccines and personal protective equipment.


Context and next steps

The hearings for both nominees represent the first formal opportunities for senators to evaluate their records and positions before proceeding toward potential confirmation votes. How the committee and the full Senate handle these nominations will determine whether the CDC and related preparedness offices obtain confirmed leadership while facing simultaneous domestic and international public health challenges.

Risks

  • Continued leadership instability at the CDC could hinder coordinated public health responses, affecting healthcare and pharmaceutical sectors that rely on CDC guidance.
  • Rising measles cases, tied to falling childhood immunization rates, pose risks to public health systems and could increase demand on hospital and pediatric services.
  • An active Ebola outbreak in the Democratic Republic of Congo and Uganda, triggering the CDC’s highest emergency response, creates international containment and resource-allocation challenges for global health and emergency preparedness sectors.

More from Stock Markets

Electra Secures Safran Production Pact for TG600 Turbogenerators Jul 15, 2026 Kepler Cheuvreux Moves Sandvik to Hold as Rally Narrows Valuation Gap Jul 15, 2026 Conagra Shares Fall After Downbeat Fiscal 2027 Guidance and Dividend Cut Jul 15, 2026 BofA Reports Surge in Financials Inflows as Q2 Earnings Season Begins Jul 15, 2026 Markets Rise as PayPal Takeover Report and Strong Earnings Drive Premarket Moves Jul 15, 2026